Gossypol Induces Apoptosis by Activating p53 in Prostate Cancer Cells and Prostate Tumor–Initiating Cells
Open Access
- 1 February 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 9 (2), 461-470
- https://doi.org/10.1158/1535-7163.mct-09-0507
Abstract
Prostate cancer continues to represent a burgeoning medical problem in the United States. Recent studies suggest that gossypol, a bioactive phytochemical produced by cotton plants, is a promising agent against prostate cancer. The current studies were undertaken to examine the chemotherapeutic efficacy of gossypol on human prostate cancer cell lines and prostate tumor–initiating cells. Gossypol reduced the viability of three prostate cancer cell lines (LAPC4, PC3, and DU145) with an IC50 between 3 and 5 μmol/L. Additionally, gossypol was effective at inhibiting prostate tumor–initiating cell-driven tumor growth in a nonobese diabetic/severe combined immunodeficient xenograft model. Our integrated molecular profiling approach encompassing proteomics, activated transcription factors, and genomics suggests that the decrease in viability was associated with increased DNA damage and the induction of apoptosis. Exposure of DU145 cells to gossypol (1–10 μmol/L) resulted in the activation of 13 proteins and 7 transcription factors, and the expression of 17 genes involved in the mitochondrial pathway of apoptosis. These studies show for the first time that gossypol treatment induces DNA damage and activates p53. Collectively, these data support the use of gossypol as a novel agent for prostate cancer. Mol Cancer Ther; 9(2); 461–70Keywords
Other Versions
This publication has 33 references indexed in Scilit:
- Effects of the sesquiterpene lactone parthenolide on prostate tumor‐initiating cells: An integrated molecular profiling approachThe Prostate, 2009
- Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and RisksEuropean Urology, 2009
- Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco ControlJNCI Journal of the National Cancer Institute, 2008
- −(−)Gossypol promotes the apoptosis of bladder cancer cells in vitroPharmacological Research, 2008
- Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and NoxaMolecular Cancer Therapeutics, 2008
- CD44+CD24− prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosisBritish Journal of Cancer, 2008
- Androgen deprivation therapy for prostate cancer: new concepts and concernsCurrent Opinion in Endocrinology, Diabetes and Obesity, 2007
- Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathwaysLife Sciences, 2007
- Investigations on gossypol: past and present developmentsExpert Opinion on Investigational Drugs, 2005
- Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin)Carcinogenesis: Integrative Cancer Research, 2005